Synthesis 2015; 47(14): 2088-2092
DOI: 10.1055/s-0034-1380549
paper
© Georg Thieme Verlag Stuttgart · New York

Syntheses of Dap-3 Polymyxin Analogues via a Tris-Boc-Protected Polymyxin B Heptapeptide

Autor*innen

  • Bryan Li*

    a   Pfizer Worldwide Research and Development, Groton Laboratories, Groton, CT 06340, USA   eMail: bryan.li@Pfizer.com
  • Anne Akin

    a   Pfizer Worldwide Research and Development, Groton Laboratories, Groton, CT 06340, USA   eMail: bryan.li@Pfizer.com
  • Thomas V. Magee

    b   Pfizer Cardiovascular, Metabolic, and Endocrine Diseases (CVMED) Chemistry, Cambridge, MA 02139, USA
  • Carlos Martinez

    a   Pfizer Worldwide Research and Development, Groton Laboratories, Groton, CT 06340, USA   eMail: bryan.li@Pfizer.com
  • Jan Szeliga

    a   Pfizer Worldwide Research and Development, Groton Laboratories, Groton, CT 06340, USA   eMail: bryan.li@Pfizer.com
  • Duc Vicki Vuong

    a   Pfizer Worldwide Research and Development, Groton Laboratories, Groton, CT 06340, USA   eMail: bryan.li@Pfizer.com
Weitere Informationen

Publikationsverlauf

Received: 18. März 2015

Accepted: 19. März 2015

Publikationsdatum:
16. April 2015 (online)


Graphical Abstract

Abstract

A semi-synthesis of a polymyxin (PMB) analogue is described. Commercially available PMB is treated with di-tert-butyl dicarbonate (Boc2O) to give globally protected PMB-Boc5, and the reaction mixture is directly carried to the highly regioselective enzymatic hydrolysis to give the cyclic heptapeptide PMBH-Boc3. After chromatographic isolation, the synthesis is completed by coupling with the tripeptide side chain, deprotection, and salt switch.

Supporting Information